Gastric cancer remains the second most common cause of cancer deaths in the world ([@bib13]). *Helicobacter pylori* (*H. pylori*) infection is considered a main risk factor for the development of gastric cancer, especially the intestinal type ([@bib10]; [@bib42]; [@bib18]; [@bib50]). It has been postulated that *H. pylori* infection causes chronic gastritis, gastric atrophy (usually with gastric intestinal metaplasia (IM)), dysplasia, and gastric cancer ([@bib9]). In this process, IM is believed to be a precancerous condition of the stomach ([@bib9]; [@bib14]; [@bib30]).

The roles of a number of genetic and epigenetic alterations---including microsatellite instability (MSI) and the promoter hypermethylation of multiple tumour-related genes---have been reported to be involved in gastric cancer and precancerous conditions of the stomach ([@bib48]; [@bib47]; [@bib5], [@bib6]; [@bib21], [@bib22], [@bib46]; [@bib29]; [@bib26]; [@bib38]; [@bib58]; [@bib37]; [@bib12]; [@bib44]; [@bib40]; [@bib27]; [@bib53]; [@bib41]). We also observed that the IM of a colonic phenotype, detected by the monoclonal antibody (mAb) Das-1 (formerly known as 7E~12~H~12~, IgM isotype) ([@bib11]), is strongly associated with gastric cancer ([@bib33]; [@bib52], [@bib53]).

A 2009 meta-analysis showed that *H. pylori* eradication seems to reduce the risk of the development of gastric cancer ([@bib15]). However, a later study from Japan showed that even after an *H. pylori* infection is cured and gastric inflammation is eliminated, the risk of the development of gastric cancer remains, and the risk increases in the background of gastric mucosal atrophy ([@bib45]). This finding provoked many arguments on whether *H. pylori* eradication would actually prevent the occurrence of gastric cancer in patients with a precancerous condition.

With respect to the effects of *H. pylori* eradication on the prevention of metachronous gastric cancer (MGC) after endoscopic resection (ER), studies based in Japan and Korea indicated that *H. pylori* treatment reduced the risk of the development of new gastric cancer in patients who underwent ER ([@bib49]; [@bib16]; [@bib2]; [@bib20]). A similar conclusion was reached in a 2014 meta-analysis ([@bib57]). However, three recent retrospective studies ([@bib28]; [@bib23]; [@bib20]) and a prospective open-label trial ([@bib7]) showed that *H. pylori* eradication did not reduce the incidence of MGC in patients who underwent ER.

Gastric cancer also occurred to some degree in *H. pylori*-negative patients who had been treated with either anti-*H. pylori* therapy or by natural eradication ([@bib16]; [@bib28]; [@bib23]; [@bib7]; [@bib2]; [@bib57]; [@bib20]), and thus the findings of other studies ([@bib28]; [@bib23]; [@bib20]) similarly raise the question of whether *H. pylori* eradication actually suppresses the development of MGC.

We reported that *H. pylori* eradication reduced the MSI and mAb Das-1 reactivity in IM ([@bib46]; [@bib52]), and a case--control study showed that patients in whom these biomarkers persist after eradication might have a high risk of developing MGC ([@bib53]). Several reports showed that *H. pylori* eradication can significantly reduce gene methylation in chronic gastritis mucosa, thus delaying or reversing *H. pylori*-induced gastric carcinogenesis ([@bib26]; [@bib6]; [@bib38]; [@bib35]). However, the changes in the molecular phenotype in the background mucosa following *H. pylori* treatment in patients who have undergone ER for gastric neoplasms remain unclear ([@bib29]; [@bib53]; [@bib41]).

In the present study, (1) we analysed the differences of molecular markers related to carcinogenesis in IM as a precancerous condition, in the background mucosa of gastric cancer patients with/without *H. pylori* infection (Study 1). (2) We also followed patients who received or did not receive *H. pylori* treatment after ER for gastric neoplasia (including noninvasive low- or high-grade neoplasia and intramucosal carcinoma) for 1 year in an open-label, randomised controlled trial (RCT), and then we examined whether *H. pylori* eradication changed the risk markers clarified in Study 1 (Study 2).

Materials and methods
=====================

Study 1
-------

### Patients and sample size

Between August 2010 and December 2013, 251 consecutive patients with a total of 298 neoplasias comprised of gastric adenomas (*n*=29) and gastric cancers (*n*=269) were treated with endoscopic submucosal resection (ESD) at Hyogo College of Medicine Hospital. The patients were 180 men (71.1%) and 71 women (28.3%), and their mean age was 71.2±9.7 years (range 23--89 years). All of the patients were Japanese. We used the criteria of the Japanese Research Society for Gastric Cancer ([@bib19]) as the histological criteria of gastric cancer and adenoma in this study. These lesions may correspond to noninvasive low- or high-grade neoplasia (Categories 3 and 4) or intramucosal carcinoma in invasive neoplasia (Category 5) based on the revised Vienna classification ([@bib39]), and thus these lesions were grouped together as the study\'s gastric cancer group (Group GC) because they represent a common end point for endoscopic therapeutic intervention.

As Study 1, we performed a cross-sectional study to clarify the differences in the molecular abnormalities in IM between gastric cancer patients and chronic gastritis patients (controls). The outcome measure that we used for the 251 patients were as follows: the prevalence of molecular alterations such as genetic and epigenetic alterations including MSI, the methylation of CpG islands at various genes, and mAb Das-1 reactivity related to gastric carcinogenesis between the *H. pylori*-positive and -negative cases. We excluded the cases of the *H. pylori*-negative patients in whom the *H. pylori* was eradicated within 1 year, because these patients were likely to have had gastric cancer at the time of *H. pylori* treatment. Patients with a history of oesophagectomy or gastrectomy were also excluded.

Microsatellite instability and other molecular markers were analysed in 131 of the 251 patients who underwent ESD. Additionally, the same molecular alterations were available in 22 *H. pylori*-positive chronic gastritis patients with IM (controls) who underwent endoscopy for a medical check-up during the same period. When the incidence of MSI is assumed to be 37.1% in Group GC and 13.6% in the control group, the above sample size can achieve a power of ∼60% to detect a difference at the level significance of *α*=0.05 (two-sided *χ*^2^ test). This presumption was based on the incidence of MSI, which was 37.1% (69 of 186) in Group GC and 13.6% (14 of 103) in the control group from our previous studies of the same patient series ([@bib46]; [@bib58]; [@bib53]). The molecular alterations in 131 patients with 131 neoplasias including 119 early gastric cancers from Group GC were compared with those in the controls. Written informed consent was obtained from all patients before the start of the study, and the study design was approved by the Ethics Committee of Hyogo College of Medicine.

### H. pylori status and DNA extraction

During each patient\'s endoscopy, three biopsy specimens were taken from the greater curvatures of the antrum and the corpus and the lesser curvatures of the angulus (one from each site). Each biopsy specimen was used for histologic examination by haematoxylin--eosin (H&E) stain, *H. pylori* status by Giemsa stain and mAb Das-1 stain, and DNA extraction. The *H. pylori* status was analysed in each patient by two methods: Giemsa staining and serum *H. pylori*-IgG antibody with an ELISA (enzyme-linked immunosorbent assay) Kit using the E plate test (Eiken Kagaku, Tokyo). A patient was regarded as positive for *H. pylori* if the result of at least one of these two methods was positive.

From paraffin-embedded blocks of the biopsy specimens, 7-*μ*m tissue sections were cut for DNA extraction. DNA was extracted only from goblet IM (incomplete type) using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany). Goblet IM was isolated via a laser capture microdissection (LCM) system, the PALM MicroBeam (Microlaser Technologies, Munich, Germany), to avoid DNA contamination of inflammatory or stromal cell nuclei based on the methodology described ([@bib46]; [@bib58]; [@bib53]) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

### Evaluation of MSI by high-resolution fluorescent microsatellite analysis

As reported ([@bib46]; [@bib58]; [@bib53]), we examined five microsatellite loci on chromosomes for MSI based on the revised Bethesda panel ([@bib51]) as follows: 2p (BAT26), 4q (BAT25), 2p (D2S123), 5q (D5S346) and 17p (D17S250). The polymerase chain reaction (PCR) products were evaluated for MSI by capillary electrophoresis using an ABI PRISM 310 Genetic analyser (Applied Biosystems, Foster City, CA, USA) and automatic sizing of the alleles using a GeneMapper (Applied Biosystems). The MSI status was judged according to previous reports ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}) ([@bib46]; [@bib58]; [@bib53]).

### Sodium bisulphite modification of DNA

The DNA was subjected to sodium bisulphite modification. In brief, purified DNA samples were chemically modified by sodium bisulphite with the EpiTect Plus DNA Bisulphite Kit (Qiagen) to convert all unmethylated cytosines to uracils while leaving the methlcytosines unaltered. The bisulphite-modified DNA was amplified using primer pairs that specifically amplify either the methylated or unmethylated sequences of the three tumour-related genes, *hMLH1*, *CDKN2A*, and *APC* (*adenomatous polyposis coli*).

### Methylation-sensitive high-resolution melting analysis

We performed a methylation-sensitive high-resolution melting (MS-HRM) analysis as described ([@bib3]). Briefly, the PCR amplification and MS-HRM analysis were performed using a LightCycler 480 Real-Time PCR System (Roche, Mannheim, Germany). Each PCR reaction mix in a 20-*μ*l total volume contained 10 *μ*l 1 × LightCycler 480 High-Resolution Melting Master mix (Roche Diagnostics, Penzberg, Germany), 1 *μ*l of 10 pmol *μ*l^−1^ of each primer for *hMLH1*, *CDKN2A* or *APC* (each; forward and reverse primer; Life Technologies Japan, Tokyo), 0.6 *μ*l nuclease-free water, and 5 *μ*l bisulphite-treated DNA template (5--10 ng *μ*l^−1^), with 3 mmol l^−1^ final MgCl~2~ for each of the three genes.

The primer sequences of all genes for the methylated and unmethylated forms, PCR, and MS-HRM conditions are summarised in [Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}. All tests were performed in duplicate. Methylated and unmethylated DNA sets (EpiTect PCR Control DNA Set; Qiagen) were used as 100% methylated and 0% unmethylated controls. Methylation standards (10% and 50%) made by diluting the fully methylated control in the unmethylated DNA were used as controls. The percentages of methylation of 0%, 10%, 50% and 100% were used to draw the standard curve ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

Methylation was scored as low (\<10%), moderate (⩾10% to\<50%), and high-level (⩾50%) methylation. When low-level methylation is detected, the biological significance is still not established ([@bib3]). Although there are a few reported cutoffs for the scoring criteria of gene methylation using the MS-HRM assay ([@bib3]; [@bib34]; [@bib1]; [@bib32]; [@bib36]), we regarded only the samples with \>10% methylation as methylated ([@bib32]; [@bib36]).

### Immunoperoxidase assays with mAb Das-1

Serial sections were stained with the mAb Das-1 (an IgM mAb highly specific against colonic phenotype) using sensitive immunoperoxidase assays as described ([@bib11]; [@bib33]; [@bib52], [@bib53]). A specimen was considered positive if both a substantial number of cells and more than one gland were reactive to this mAb ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). If only occasional goblet cells were stained, then the sample was defined as negative ([@bib11]; [@bib33]; [@bib52], [@bib53]).

Study 2
-------

### Patients

We performed an open-label RCT to determine whether *H. pylori* treatment changed the molecular markers in IM in *H. pylori*-positive patients who underwent ESD during the same period as that of Study 1. All patients who showed positivity for MSI in Study 1 were enrolled in this RCT. The exclusion criteria were as follows: (1) patients with malignancy in other organs; (2) patients with an allergy to drugs used for *H. pylori* eradication; (3) a past episode of *H. pylori* treatment; (4) patients regularly taking a nonsteroidal anti-inflammatory drug, including aspirin; (5) patients with a history of oesophagectomy or gastrectomy; and (6) patients who were determined by their physicians to be unqualified for any other reason. In the cases of patients who were histologically diagnosed based on the finding that the resected lesion of ESD showed submucosal invasion (\>500 *μ*m) or those with positive lymphovascular invasion, surgery was recommended. A follow-up endoscopy with biopsies was performed at 1 year after intervention to assess the changes in molecular markers.

### Outcome measures

The primary end point of Study 2 was the changes in MSI between the *H. pylori*-eradicated and non-eradicated groups at 1 year among the *H. pylori*-positive patients. Secondary end points were the alterations of other molecular markers, that is, CpG island methylation evaluated in Study 1 and mAb Das-1 reactivity in IM. Study 2 was conducted at our college hospital according to the Declaration of Helsinki and adhered to good clinical practices. The study protocol was approved by the Ethics Committee of our college. Informed written consent was obtained from all participants before they entered the study. This trial is registered with the UMIN Clinical Trials Registry (number UMIN000006206).

### Randomisation, therapy, and follow-up

Randomisation was performed by drawing lots from a sealed envelope that contained a preassigned random treatment: the *H. pylori*-eradicated group or the non-eradicated group. The patients in the eradicated group (*n*=22) received lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 mg two times daily for 1 week. The patients in the non-eradicated group (*n*=19) received standard care but no antibiotics for eradication. Whether the eradication succeeded or not was established by the administration of a ^13^C urea breath test to each patient 6--8 weeks after the completion of the *H. pylori* treatment.

Participants in whom the eradication treatment failed were invited to receive the second-line therapy: lansoprazole 30 mg, amoxicillin 750 mg, and metronidazole 250 mg, all two times daily for 1 week. *H. pylori* status was checked by the same procedures as those used to confirm infection at baseline. Following successful treatment results, all patients were then prospectively followed up for 1 year. In both patient groups, biopsy specimens were taken from the same portions in the same manner as that used at baseline after intervention, as described in Study 1.

### Sample size

Our previous case--control study ([@bib53]) showed that the improved incidence of MSI in IM at 1 year after *H. pylori* treatment was ∼70% in the eradicated group and 15% in the non-eradicated group. Based on this result, in the present study, we therefore calculated that we needed to have 16 *H. pylori*-positive patients showing MSI in each group to have a power of 80% to detect a difference at the level significance of *α*=0.05 (two-sided). Considering a 10% patient loss to follow-up, we calculated that at least 18 patients in each group (36 in total) were required.

### Statistical analysis

Continuous data are reported as means with standard deviations (s.d.\'s), and categorical data are provided as frequencies with proportions. The data were assessed by Welch\'s *t*-test assuming unequal variances between two independent groups and by the *χ*^2^ test or Fisher\'s exact test for comparisons between two proportions in Studies 1 and 2. In Study 1, a multivariate logistic regression analysis was also performed to identify the molecular alterations associated with gastric neoplasia. All statistical tests were two-sided, and *P*-values \<0.05 were considered significant. Statistical analyses were performed with GraphPad Prism5 (GraphPad Software, La Jolla, CA, USA) or StatView version 5.0 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Study 1
-------

### Patient characteristics

The characteristics of the Study 1 patients are shown in [Table 1](#tbl1){ref-type="table"}. Twenty-nine patients (22.1%) were found to be negative for *H. pylori*. Of these patients, eight had undergone *H. pylori* treatment more than 1 year earlier. The remaining 21 patients were not previously treated for *H. pylori* eradication, and their infections were thus considered naturally eradicated. The endoscopic findings of all 21 patients revealed atrophic gastritis. Of these patients, severe atrophic gastritis (open type, O-II to -III) according to the Kimura and Takemoto classification ([@bib24]) was identified in 19 patients (90.5%). This result strongly suggests a past *H. pylori* infection. There were no significant differences in age, gender, smoking, or body mass index among the *H. pylori*-positive and -negative groups and the controls.

### Microsatellite instability, epigenetic alterations, and mAb Das-1 reactivity

The incidence of MSI, hypermethylation at three genes, and mAb Das-1 reactivity to IM did not show significant differences among all neoplasia cases (Group GC), regardless of the presence or absence of *H. pylori* infection ([Table 2](#tbl2){ref-type="table"}). In contrast, MSI showed significantly higher incidences in the Group GC, including *H. pylori*-positive and -negative cases compared with those in the non-neoplasia (control) group (*P*=0.008 and *P*=0.02, respectively). Monoclonal antibody Das-1 reactivity against IM was also frequently observed in the Group GC patients whether they were positive or negative for *H. pylori* infection compared with the controls (*P*=0.07, both). In the multivariate logistic regression analysis, these two markers were significantly associated with gastric neoplasia (odds ratio (OR)=5.06, 95% confidence interval (CI) 1.41--18.09, *P*=0.01 for MSI; OR=2.51, 95% CI: 0.96--6.55, *P*=0.06 for mAb Das-1 reactivity).

Microsatellite instability is thought to be significantly associated with loss of *hMLH1* gene ([@bib51]). Of the 61 MSI-positive cases in the present study, (58 in Group GC and 3 controls), only 13 patients (21.3%) showed positivity for hypermethylation at *hMLH1*, suggesting that deficiencies in not only *hMLH1* but also other mismatch repair genes may cause MSI in IM.

Study 2
-------

### Patient characteristics

From November 2010 to May 2012, a total of 251 patients who underwent ESD were screened and 210 were excluded; 41 were enrolled in Study 2. The patients who showed positivity for MSI were allocated to the eradicated (*n*=22) and non-eradicated (*n*=19) groups, and were followed over a 1-year period. Two patients in the eradicated group and two patients in the non-eradicated groups dropped out during the follow-up. Out of these four patients, one patient in the non-eradicated group was transferred to another hospital for the treatment of acute renal failure. The two patients in the eradicated group and the other patient in the non-eradicated group did not return for follow-up at 1 year despite repeated calls. One patient in the eradicated group was excluded because the patient underwent surgery because of submucosal invasion. The respective dropout rates were 9.1% and 10.5% in the eradicated and non-eradicated groups, respectively, which are not significantly different. A final total of 36 patients were included in the analysis (CONSORT flow chart for Study 2; [Figure 1](#fig1){ref-type="fig"}). The baseline characteristics illustrating that there were no other significant differences between the eradicated and non-eradicated groups are shown in [Table 3](#tbl3){ref-type="table"}.

### Microsatellite instability changes between baseline and at 1 year after the intervention

The baseline incidence of molecular alterations in IM was balanced between the eradicated and non-eradicated groups ([Table 4](#tbl4){ref-type="table"}). At 1 year after the intervention, the condition of MSI in the IM changed to stable in 73.7% (14 of 19) of the eradicated group patients and in 58.8% (10 of 17) of the non-eradicated group patients, with no significant difference in the change of MSI after the intervention between the groups ([Table 5](#tbl5){ref-type="table"}).

### Changes of other molecular markers between baseline and 1 year after the intervention

At baseline, the incidence of promoter methylation at *hMLH1*, *CDKN2A*, and *APC* genes and the mAb Das-1 reactivity were not significantly different between the eradicated and non-eradicated groups ([Table 4](#tbl4){ref-type="table"}). At 1 year fter the intervention, most cases showed unchanged molecular alterations in both groups, and the incidences of improved molecular markers were also not significantly different between the eradicated and non-eradicated groups (by Fisher\'s exact test) ([Table 5](#tbl5){ref-type="table"}).

Discussion
==========

This is the first RCT that showed whether *H. pylori* eradication improves the molecular markers related to carcinogenesis in the background mucosa of patients who underwent ER for gastric neoplasia. Our results showed that MSI and mAb Das-1 reactivity in IM were detected significantly more frequently in the patients with neoplasias (Group GC) compared with the controls, thus suggesting that MSI and mAb Das-1 reactivity in IM are associated with gastric neoplasia as reported ([@bib46]; [@bib58]; [@bib53]). Interestingly, the incidences of MSI and mAb Das-1 reactivity in IM were not significantly different between the *H. pylori*-positive and -negative patients with neoplasia. These results therefore indicate that *H. pylori* eradication may not change the course of molecular alterations once gastric cancer has occurred in the stomach. Indeed, the open-label RCT in Study 2 showed that *H. pylori* eradication did not provide a significant reversal of any molecular alterations compared with no treatment for *H. pylori* infection.

Gastric cancer is frequently associated with a background of IM, which is the hallmark precancerous condition in *H. pylori*-associated gastric carcinogenesis ([@bib9]; [@bib14]; [@bib30]). The molecular signatures identified in IM as well as in neoplasias are thus likely to represent molecular markers of *H. pylori*-associated gastric cancer pathways. Several studies, including ours, showed that MSI may have a role in early events leading to gastric carcinogenesis ([@bib8]; [@bib4]; [@bib17]; [@bib46]; [@bib58]; [@bib43]; [@bib53]). The results of the present study indicated that MSI could be a risk marker for identifying 'high-risk\' IM related to gastric carcinogenesis.

In addition, the patients\' MSI status did not show a significant alteration following the eradication as the primary end point in our RCT. According to two RCTs from Japan and Korea, the effects of *H. pylori* eradication on the prevention of MGC after ER are still controversial ([@bib16]; [@bib7]). Although a recent meta-analysis showed that eradication reduced the occurrence of MGC (OR=0.42, 95% CI: 0.32--0.56) ([@bib57]), a study that followed-up many patients (*n*=1258) for a long time (up to 5 years) ([@bib23]) was not included in the meta-analysis. Taking into account other relevant studies ([@bib28]; [@bib23]; [@bib20]) and our molecular study and RCT, it remains possible that *H. pylori* eradication may not be effective for the prevention of the development of MGC.

In contrast to our results, [@bib15] stated that based on their meta-analysis, *H. pylori* treatment seems to reduce the risk of gastric cancer. However, the patients in their meta-analysis were heterogeneous populations consisting of chronic gastritis, dysplasia, and early cancer. The difference in study populations may be the reason for the differing results between our findings and the conclusion by [@bib15]. It is evident that gastric cancer still occurs to some degree after the ER of gastric cancer and successful eradication of *H. pylori* ([@bib55]; [@bib16]), and multiple gastric cancers are commonly observed in \>10% of patients with gastric cancer ([@bib31]). Namely, the background mucosa once gastric cancer has developed may have a high risk for MGC development compared with chronic gastritis mucosa without neoplasia. Indeed, in the present study the incidence of MSI and mAb Das-1 reactivity was significantly higher in the patients with gastric cancer (Group GC) compared in those without (chronic gastritis patients as controls).

*Helicobacter pylori* infection has been shown to contribute to the hypermethylation of various genes involved in gastric carcinogenesis ([@bib48]; [@bib47]; [@bib5], [@bib6]; [@bib21], [@bib22]; [@bib26]; [@bib29]; [@bib38]; [@bib12]; [@bib37]; [@bib40]; [@bib44]; [@bib27]). It was reported that the DNA methylation of the promoter region of several genes ([@bib6]; [@bib26]; [@bib38]; [@bib40]) was reversed after *H. pylori* eradication therapy in chronic gastritis patients. Generally, CpG island hypermethylation can be induced by chronic inflammation ([@bib6]; [@bib38]), and methylation profiles obtained from noncancerous gastric mucosae could be affected by the activity of gastritis. The methylation levels observed during a currently active *H. pylori* infection may thus not necessarily reflect the future risk of developing gastric cancer ([@bib35]). All of the previous studies of methylation were conducted using DNA extracted from the whole biopsy tissues, and thus their results were affected by the contamination of inflammatory cells. Namely, the elimination of inflammatory cells by *H. pylori* treatment may affect the reverse of methylation in cases in which whole biopsy samples are used. In our present study, therefore, we used LCM to avoid the DNA contamination of inflammatory or stromal cell nuclei.

Previous studies of the molecular changes induced by *H. pylori* eradication were focused exclusively on chronic gastritis mucosa without gastric neoplasia (non-neoplastic mucosa), although a few studies reported the effects of eradication on CpG methylation in the background mucosa with gastric cancer ([@bib35]; [@bib41]). In addition, epigenetic alterations were evaluated mostly by methylation-specific PCR (MSP). Although MSP has high analytical sensitivity and is the most widely used method for the analysis of DNA methylation, the method has some limitations; it gives many false-positive results and is qualitative ([@bib25]). The MS-HRM analysis used in our study is applicable for the very sensitive and semiquantitative assessment of methylation levels in an unmethylated background ([@bib54]).

[@bib41] investigated the changes in the DNA methylation after eradication in the background mucosa with cancer, as in the present study. Their results are similar to ours: a decrease in the *MOS* methylation level was not observed among patients with IM or those with neoplasias including gastric cancer, and the methylation level in *MOS* was persistently increased in the patients with gastric cancer (*P*\<0.01) even after *H. pylori* eradication ([@bib41]). In contrast, [@bib35] showed that the FLNc and THBD methylation levels quantified by real-time MSP were significantly decreased at 1 year in patients who had undergone ER, and this result was correlated with the degree of inflammatory cell infiltration.

We observed in this RCT that MSI changed to a stable status or newly developed methylation to some degree in the non-eradicated group, and that MSI occurred or epigenetic alterations changed from unmethylated to methylated status in some cases in the eradication group -- a phenomenon that is difficult to explain. One possibility is that MSI and gene methylation events are not always uniformly distributed throughout the stomach ([@bib38]). Indeed, the biopsy specimens evaluated here in the RCT may not coincide completely between the baseline and at 1-year follow-up, and thus the possibility of sampling error cannot be ruled out. In addition, a certain condition, that is, the extension of IM with molecular events, is consistent with the hypothesis of field cancerisation of the stomach, and thus *H. pylori* therapy may not be able to reverse the course of gastric carcinogenesis ([@bib58]).

Individuals with residual methylation after *H. pylori* eradication may have a risk of gastric cancer development. [@bib55] reported that they observed no overall reduction of cancer development by *H. pylori* treatment in their patient subgroup with precancerous lesions, that is, atrophic gastritis or IM. Thus, they emphasised the concept of a 'point of no return\' ([@bib55]; [@bib56]) in which the benefits of *H. pylori* eradication diminish after the IM stage reaches a point at which molecular changes are irreversible. Our present findings may support their conclusion, which is that once gastric cancer has developed in the background mucosa with IM, *H. pylori* treatment may not be helpful to change the course.

The present study has the following three limitations. First, this was a study from a single institution with a small number of patients who underwent ESD. Second, the number of cases analysed in the RCT was small, particularly considering that several different molecular markers and cellular phenotypes were compared. In the number of cases evaluated (19 cases in the eradicated group and 17 cases in the non-eradicated group), the improved incidences of MSI were 73.7% in the eradication group *vs* 58.8% in the non-eradicated group, which were different from the improved incidences that were a *priori* assumed to calculate the sample size in Study 2, that is, 70% *vs* 15%, respectively. In fact, the statistical power that detects a difference in the improved incidence of stable MSI after the intervention was 10% at the significance level of *α*=0.05 (two-sided) by Fisher\'s exact test. This lack of power may thus have affected the present results in which a significant change of MSI (the primary end point) by the intervention was not identified, thus indicating that our findings in the RCT might be underestimated. Also, the statistical power of sample size may be somewhat weak (∼60%) in Study 1. However, the incidence of all molecular alterations did not show significant differences between the *H. pylori*-positive and -negative patients who underwent ESD for gastric neoplasia (Study 1), and this result may thus compensate for the lack of statistical power in the RCT (Study 2). Nevertheless, we believe that the data presented in the present study are of value, and that they will generate further efforts among researchers to extend these studies. Third, as the intervention period of the RCT was short, it may be necessary to conduct follow-ups for a long time, for example, more than 1 year. [@bib7] postulated that a long-term investigation (over 5 years) could clarify the exact role of *H. pylori* eradication. Changes in a cellular phenotype (as identified by mAb Das-1 reactivity) by *H. pylori* treatment require substantial time, as we mentioned ([@bib53]).

In conclusion, we found that (1) MSI and mAb Das-1 reactivity in IM are markers of the risk of cancer development; (2) there were no significant differences in MSI or other molecular events in IM between *H. pylori*-positive and -negative patients who underwent ER; and (3) an RCT did not show significant molecular changes in IM between the eradicated and non-eradicated groups. These results indicate that the cure of *H. pylori* may not prevent MGC in the background mucosa with IM.
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###### Characteristics of the patients examined in Study 1

                             **Group GC**   **Control (%)**                     
  ------------------------- -------------- ----------------- ----------- ------ ------
  Mean age±s.d. (years)        72.8±7.5        71.4±10.4      68.3±12.7   0.12   0.33
  Male : Female                72 : 30          20 : 9         14 : 8     0.52   0.69
  Alcohol drinking            35 (34.3)        13 (44.8)      9 (40.9)    0.56   0.78
  Current smoking             18 (17.6)        5 (17.2)       8 (57.1)    0.13   0.22
  Mean BMI±s.d.(kg m^−2^)      22.8±3.2        23.2±4.5       22.2±3.0    0.35   0.57

Abbreviations: BMI=body mas index; GC=gastric cancer.

###### Comparison of molecular alterations between Group GC and the controls

                          **Group GC**                        **Control (%)**                                                          
  ---------------------- -------------- ----------- ----------------------------------- ---------- ----------------------------------- -----------------------------------
  MSI                      45 (44.1)     13 (44.8)                 0.95                  3 (13.6)   0.008[a](#t2-fn2){ref-type="fn"}     0.02[a](#t2-fn2){ref-type="fn"}
  *hMLH1*                  30 (29.4)     7 (24.1)                  0.58                  6 (27.3)                 0.84                                0.80
  *CDKN2A*                  1 (1.0)        0 (0)     \>0.99[a](#t2-fn2){ref-type="fn"}    0 (0)     \>0.99[a](#t2-fn2){ref-type="fn"}   \>0.99[a](#t2-fn2){ref-type="fn"}
  *APC*                     9 (8.8)      3 (10.3)     0.73[a](#t2-fn2){ref-type="fn"}    5 (22.7)    0.13[a](#t2-fn2){ref-type="fn"}     0.27[a](#t2-fn2){ref-type="fn"}
  mAb Das-1 reactivity     59 (57.8)     18 (62.1)                 0.68                  8 (36.4)                 0.07                                0.07

Abbreviations: *APC*=*adenomatous polyposis coli*; GC=gastric cancer; mAb=monoclonal antibody; MSI=microsatellite instability.

Fisher\'s exact test.

###### Baseline characteristics of a randomised controlled trial (Study 2)

                              **Eradicated group (%) (*****n*****=22)**   **Non-eradicated group (%) (*****n*****=19)**            ***P-value***
  -------------------------- ------------------------------------------- ----------------------------------------------- ---------------------------------
  Mean age±s.d. (years)                       72.5±7.8                                      73.8±7.1                                   0.69
  Male : Female                                17 : 5                                        12 : 7                                    0.32
  Alcohol drinking                            6 (27.3)                                      9 (47.3)                                   0.18
  Current smoking                             3 (13.6)                                      4 (21.1)                      0.68[a](#t3-fn2){ref-type="fn"}
  Mean BMI±s.d. (kg m^−2^)                    23.8±2.4                                      22.8±3.0                                   0.44

Abbreviation: BMI=body mas index.

Fisher\'s exact test.

###### Summary of molecular alterations at baseline (Study 2)

                          **Eradicated group (%) (*****n*****=22)**   **Non-eradicated group (%) (*****n*****=19)**           ***P*****-value**
  ---------------------- ------------------------------------------- ----------------------------------------------- -----------------------------------
  MSI                                     22 (100)                                      19 (100)                                     ---
  *hMLH1*                                 5 (22.7)                                      3 (15.8)                       0.70[a](#t4-fn2){ref-type="fn"}
  *CDKN2A*                                 1 (4.5)                                        0 (0)                       \>0.99[a](#t4-fn2){ref-type="fn"}
  *APC*                                     0 (0)                                       3 (15.8)                       0.09[a](#t4-fn2){ref-type="fn"}
  mAb Das-1 reactivity                    15 (68.2)                                     13 (68.4)                                   0.99

Abbreviations: *APC*=*adenomatous polyposis coli*; mAb=monoclonal antibody; MSI=microsatellite instability.

Fisher\'s exact test.

###### Changes in molecular markers revealed by the randomised controlled trial (Study 2)

                          **Eradicated group**   **Non-eradicated group**                                                      
  ---------------------- ---------------------- -------------------------- ---------- ----------------- ----------- ---------- ---------------
  MSI                          14 (73.7)                 5 (26.3)             ---         10 (58.8)      7 (41.2)      ---          0.48
  *hMLH1*                   4 (21.1)^**a**^             11 (57.9)           4 (21.1)   2 (11.8)^**a**^   12 (70.6)   3 (17.6)    0.66^**a**^
  *CDKN2A*                   1 (5.3)^**b**^             18 (94.7)            0 (0)      0 (0)^**b**^     17 (100)     0 (0)     \>0.99^**b**^
  *APC*                       0 (0)^**c**^              18 (94.7)           1 (5.3)    2 (11.8)^**c**^   14 (82.4)   1 (5.9)     0.22^**c**^
  mAb Das-1 reactivity       1 (5.3)^**d**^             15 (78.9)           3 (15.8)   1 (5.9)^**d**^    11 (64.7)   5 (29.4)   \>0.99^**d**^

Abbreviations: MSI=microsatellite instability; *APC*=*adenomatous polyposis coli*; mAb=monoclonal antibody.*P*-value\*, Fisher\'s exact test.

^**a**,**b**,**c**,**d**^*P*-values indicate the comparison in the prevalence of improved cases between the eradicated and non-eradicated groups.
